10 January 2025, New Delhi: Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers, has announced an investment of ₹940 crore in Neuberg Diagnostics. This strategic infusion aims to bolster Neuberg's inorganic expansion and technological advancements as the company prepares for an upcoming initial public offering (IPO). 

Rahul Shah, Partner at Kotak Alternate Asset Managers, expressed confidence in Neuberg's vision, stating that the investment is expected to enhance the company's scale and readiness for the IPO. Dr. GSK Velu, Founder and Managing Director of Neuberg Diagnostics, indicated that the funding would be utilized to expand capabilities in personalized medicine, integrated diagnostics, and to extend the company's footprint across India. 

Neuberg Diagnostics, established in 2017, operates in India, the UAE, Sri Lanka, and South Africa, offering a wide range of pathological tests. The company processes over 4 million patient samples and conducts 16 million tests annually. 

This investment aligns with Kotak Strategic Situations Fund's strategy of providing solution capital through efficient financing structures, focusing on strategic investment opportunities and restructuring prospects across various sectors in India. 

The Indian diagnostics industry is experiencing significant growth, with the market valued at $16 billion in 2023 and projected to reach $43.57 billion by FY32. Factors contributing to this expansion include increased healthcare spending, rising income levels, and greater awareness of preventive testing. 

Neuberg's strategic initiatives, supported by this substantial investment, position the company to capitalize on the industry's growth trajectory and to meet the evolving needs of clinicians and patients.